Chimeric bivalent blood-pressure-reduction vaccine for human vascular smooth muscle cell L-type calcium channels and angiotensin 1-type receptors and application thereof

A technology of vascular smooth muscle and angiotensin, applied in the field of chimeric bivalent antihypertensive vaccine, can solve the problems of single target, feedback activation of renin-angiotensin system, high titer of vaccine carrier antibody, etc., and achieve good antihypertensive blood pressure effect, blood pressure lowering effect

Active Publication Date: 2019-04-23
WUHAN HUAJIYUAN BIOTECH DEV
View PDF7 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] The purpose of the present invention is to provide an anti-inflammatory vaccine against the problems of a single target, feedback activation of the renin-angiotensin system, and excessively high antibody titers of the vaccine carrier for the existing therapeutic hypertension vaccine against angiotensin II. Chimeric bivalent antihypertensive vaccine of L-type calcium channel and angiotensin-1 receptor in human vascular smooth muscle cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Chimeric bivalent blood-pressure-reduction vaccine for human vascular smooth muscle cell L-type calcium channels and angiotensin 1-type receptors and application thereof
  • Chimeric bivalent blood-pressure-reduction vaccine for human vascular smooth muscle cell L-type calcium channels and angiotensin 1-type receptors and application thereof
  • Chimeric bivalent blood-pressure-reduction vaccine for human vascular smooth muscle cell L-type calcium channels and angiotensin 1-type receptors and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] Example 1 Screening and Preparation of Four Amino Acid Sequences of Human Vascular Smooth Muscle Cell L-type Calcium Channel Epitope

[0056] Based on bioinformatics techniques such as amino acid hydrophilicity, antigenicity, and sequence space conformation to predict B cell epitopes, four amino acid sequences targeting human vascular smooth muscle cell L-type calcium channel epitopes were designed: VPAEDDPSPC, DSSKQTEAECK, DSHTEDKGPI , CAPESEPSNSTE. A PSSM-8 automatic peptide synthesizer (SHIMADZU, Japan) was used to synthesize peptides, and the purity of the synthesized peptides was analyzed by high performance liquid chromatography to reach more than 95%. The obtained peptides were lyophilized, aliquoted, placed in cryopreservation tubes, and stored at -80°C for later use.

Embodiment 2

[0057] Example 2 Combination Design of Target Molecular Epitopes Related to the Pathogenesis of Hypertension

[0058] Using the combination of the above four human vascular smooth muscle cell L-type calcium channel antigen epitopes and the human angiotensin type 1 receptor antigen CQ10 epitope / angiotensin II epitope sequence, various target molecular epitope combinations related to the onset of hypertension are formed as follows surface:

[0059]

[0060] Note: The amino acid sequence "GSG" is used to connect the above epitope sequences, and the epitope combination of target molecules related to hypertension is not limited to the combination of human vascular smooth muscle cell L-type calcium channel antigen epitope and human angiotensin 1 Type receptor antigen CQ10 epitope / angiotensin II combination; two existing hypertension-related target molecular epitopes can be composed.

Embodiment 3

[0061] Embodiment 3 recombinant hepatitis B core protein monomer molecular design

[0062] The epitope combinations of target molecules associated with the onset of hypertension in the above table can be inserted into any site between the 76th and 82nd amino acids in the amino acid sequence of the immunogenic carrier (SEQID No.1),

[0063] Alternatively, an amino acid sequence of any length between the 76th and 82nd amino acids in the amino acid sequence of the immunogenic carrier is replaced by a combination of target molecular epitopes related to the onset of hypertension; The combined form of CQ10-" is used as an example to construct recombinant hepatitis B core protein monomer molecules:

[0064] a. Insert the combination of "-CE12-CQ10-CE12-CQ10-" between the 80th and 81st amino acids in the immunogenic carrier amino acid sequence (SEQ IDNo.1): "--WVGTNMEDPA--CAPESEPSNSTEGSGAFHYESQGSGCAPESEPSNSTEGSGAFHYESQ--SRDLVVSYVN --";

[0065] b. The combination of "-CE12-CQ10-CE12...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a chimeric bivalent blood-pressure-reduction vaccine for human vascular smooth muscle cell L-type calcium channels and angiotensin 1-type receptors and application thereof. Thechimeric bivalent blood-pressure-reduction vaccine comprises icosahedron virus-like particles formed by self-assembling 180 or 240 recombinant hepatitis B core protein monomer molecules, and the recombinant hepatitis B core protein monomer molecules are formed by immunogenic carriers as skeletons and high-blood-pressure attack related target-molecule epitope combinations. According to the chimeric bivalent blood-pressure-reduction vaccine for the human vascular smooth muscle cell L-type calcium channels and the angiotensin 1-type receptors and the application thereof, according to a molecularstructure and the immunological characteristics of a hepatitis-B core antigen, and combined with actual defects of current high-blood-pressure vaccine development, the therapeutic blood-pressure-reduction vaccine for multiple target points is designed; the therapeutic blood-pressure-reduction vaccine can induce and generates specific antibodies for multiple therapeutic target points respectively,the combined blood-pressure-reduction effect is developed, and blood pressure of a high-blood-pressure animal model is effectively reduced.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to a chimeric bivalent antihypertensive vaccine targeting human vascular smooth muscle cell L-type calcium channel and angiotensin-1 receptor and application thereof. Background technique [0002] Hypertension is the most common chronic disease and has become the primary risk factor for cardiovascular disease, chronic kidney disease and diabetes. Its major complications such as stroke, myocardial infarction, heart failure and chronic kidney disease not only cause disability and mortality High, and seriously consume medical and social resources, causing a heavy burden on the family and the country. In recent decades, the number of hypertensive patients in my country has increased dramatically. At present, the prevalence of hypertension in China is 25.2%, and there are 270 million hypertensive patients in the country (2014). Although chemical drugs such as angiotensin II receptor blocker...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/00A61K39/385A61P9/12C07K19/00
CPCA61K39/0005A61K39/385A61P9/12C07K14/005C07K14/705C07K14/72C07K2319/00C12N2730/10123C12N2730/10143C12N2730/10122A61K2039/70A61K2039/6075A61K2039/55505
Inventor 廖玉华陈霄吴海浪邱志华廖梦阳
Owner WUHAN HUAJIYUAN BIOTECH DEV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap